Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP), a biopharmaceutical development company, is focused on acquiring and developing innovative products designed to treat a variety of human diseases. Currently, the company is developing a portfolio of metabolically inert antifolate compounds engineered to have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders. Chelsea Therapeutics purposes to create value by building a world-class team, accelerating the development of its product candidates and expanding its therapeutic pipeline. For further information, visit the Company’s web site at www.chelseatherapeutics.com.
- 17 years ago
QualityStocks
Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Profit Momentum Builds for Beeline Holdings Inc. (NASDAQ: BLNE) as Next-Gen Platform Accelerates
Beeline Holdings (NASDAQ: BLNE), a fast-growing digital mortgage platform redefining the path to homeownership, recently…
-
QualityStocksNewsBreaks – Why SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) Is ‘One to Watch’
Disseminated on behalf of SPARC AI Inc. and may include paid advertising. SPARC AI (CSE: SPAI) (OTCQB:…
-
QualityStocksNewsBreaks – BCII Enterprises Inc. (OTCID: BCII) Details Real-World Applications for Patent-Pending Coupon Token Architecture
BCII Enterprises (OTCID:BCII) today announced real-world applications for its patent-pending Coupon Token architecture, as detailed…